profit from every CHF 100 of sales.
CHF 0CHF 100
Siegfried
CHF 70.25-1.40% today
-2.2% in 1 year
1-year low CHF 66.901-year high CHF 100.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay CHF 18.25 for every CHF 1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Siegfried sold, what it kept, and what it did with the cash.
Sales went from CHF 1.23 billion in 2022 to CHF 1.33 billion in 2025, with CHF 169 million of profit last year.
SalesProfit
Siegfried vs. similar companies
Siegfried grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Siegfried | 18.2× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Siegfried's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,230 | 1,271 | 1,295 | 1,328 | |
| 319 | 320 | 329 | 354 | |
| 229 | 169 | 195 | 216 | |
| 308 | 241 | 289 | 311 | |
| 156 | 113 | 160 | 169 | |
| 3.63 | 2.62 | 3.69 | 3.84 | |
| 25.9% | 25.2% | 25.4% | 26.7% | |
| 18.6% | 13.3% | 15.0% | 16.3% | |
| 12.7% | 8.9% | 12.4% | 12.7% |
Balance sheet
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,793 | 1,862 | 1,934 | 2,154 |
| Cash | 91 | 56 | 39 | 103 |
| Total debt | – | – | – | – |
| Total liabilities | 1,002 | 1,023 | 954 | 1,026 |
| 791 | 838 | 980 | 1,128 | |
| 43 | 43 | 43 | 44 | |
| 24.3% | 16.2% | 17.8% | 16.3% | |
| 19.8% | 13.5% | 16.3% | 15.0% |
Cash flow
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 142 | 209 | 169 | 228 | |
| 115 | 137 | 181 | 231 | |
| 27 | 72 | -12 | -3 | |
| Dividends paid | 14 | 14 | 15 | 17 |
| 24 | 6 | 19 | 0 | |
| 10 | 10 | 0 | 8 |
Valuation
- 18.2×
- –
- 9.55
- 2.8×
- 2.3×
- –
- 9.6×
- -0.1%
- 5.5%
- 0.5%
Profitability
- 26.7%
- 16.3%
- 12.7%
- –
- 16.3%
- 18.6%
- –
- –
- –
- –
Growth
- +2.6%
- +1.9%
- –
- –
- +0.5%
Financial health
- -0.3×
- –
- –
- 30.4×
- 2.00
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 13%of 963
Top 33%of 894
Top 30%of 632
Bottom 22%of 908
Bottom 37%of 991
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
9.9% of its profit
Room to growStretchedMore than it earnsNews
Siegfried Holdings Non-GAAP EPS of CHF 1.56, revenue of CHF 633M; reaffirms FY outlookSeeking Alpha · Aug 21, 2026The newest story we have is from Aug 21, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
55No pass
Philip Fisher
47No pass
Peter Lynch
14No pass
Joel Greenblatt
45No pass
Charlie Munger
55No pass
Terry Smith
40No pass
Questions about Siegfried
Is Siegfried a good stock to buy?
A solid business at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Siegfried AI analysis
What does Siegfried do?
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. It is in Drug Manufacturers - Specialty & Generic, based in Zofingen, Switzerland, with 3,891 employees.
Does Siegfried pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 10% of its yearly profit. In 2025 it paid out CHF 16.6 million in dividends.
How has Siegfried stock done over the past year?
Down 2.2% over the past twelve months, to CHF 70.25. It traded between CHF 66.90 and CHF 100.00 and is 29.8% below its high.
Who are Siegfried's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Siegfried's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.